Inogen Reports Preliminary FY25 Revenue of $349M
Reports preliminary FY25 revenue $349M, consensus $355.5M. "While fourth quarter results continued to reflect strong performance in our business-to-business channels, we experienced a shift in the timing of a few large customer orders into the first half of 2026. Although this delay relative to expectations is disappointing, our full year results continued to make meaningful progress in executing our business turnaround," said Kevin Smith, president and CEO. "Highlights for the full year include positive revenue growth, advancing toward profitability, and expanding the innovation pipeline with launches of the Voxi 5 stationary oxygen concentrator and Aurora Masks for Obstructive Sleep Apnea patients in the U.S. The Inogen team remains confident in our ability to drive growth acceleration and profitability into 2026, and we look forward to sharing additional details and 2026 financial guidance during our February earnings call."
Trade with 70% Backtested Accuracy
Analyst Views on INGN
About INGN
About the author
Inogen Launches Aurora CPAP Masks, Expanding into Sleep Therapy Market
- Product Innovation: Inogen's launch of the Aurora CPAP masks marks a significant milestone in its respiratory care portfolio, aimed at providing high-quality masks for patients with obstructive sleep apnea, thereby expanding market opportunities.
- Market Positioning: Designed for superior comfort and reliability, the Aurora masks enhance Inogen's competitiveness in the rapidly growing sleep therapy market, with plans to leverage existing distribution channels to strengthen relationships with healthcare providers.
- User Feedback: A patient-use study involving 140 participants revealed that the majority reported high satisfaction with the Aurora masks, indicating strong market acceptance and potential for sales growth.
- Technical Advantages: Featuring high-quality headgear and medical-grade silicone cushions, the Aurora masks provide a comfortable fit and are universally compatible with most CPAP devices, meeting FDA 510(k) standards for safety and performance.
Inogen Launches Aurora CPAP Masks, Expanding into Sleep Apnea Market
- Product Innovation: Inogen's launch of the Aurora CPAP masks marks a significant advancement in its home respiratory solutions, aimed at addressing the needs of patients with obstructive sleep apnea, thereby broadening its market coverage.
- Market Opportunity: Designed for superior comfort and reliability, the Aurora masks are expected to enhance Inogen's competitiveness in the rapidly growing sleep therapy market, further increasing its market share.
- Customer Satisfaction: A patient-use study involving 140 participants revealed that the majority reported high satisfaction with the Aurora masks, establishing a solid foundation for Inogen's market entry.
- Strategic Partnerships: Inogen plans to leverage its existing distribution channels and partnerships to bring the Aurora masks to market, strengthening relationships with healthcare providers and reinforcing its leadership position in home respiratory care.
Three MedTech Pioneers Transforming Healthcare by 2026: AVAH, INGN, and CCLD
Healthcare Innovation Focus: Investors are increasingly interested in companies that innovate healthcare delivery to reduce costs and improve quality, particularly in ambulatory and home care settings, amid rising healthcare expenses and workforce shortages.
Aveanna Healthcare Overview: Aveanna Healthcare is positioned for growth with a diverse service mix in home care, expecting significant revenue increases and operational momentum, despite potential risks from labor costs and reimbursement policies.
Inogen's Market Position: Inogen specializes in portable oxygen concentrators, showing signs of recovery and growth through innovation and cost discipline, making it a notable player in the respiratory care market for 2026.
CareCloud's Technological Advancements: CareCloud offers a comprehensive suite of healthcare IT solutions, focusing on AI-driven efficiencies to improve operational performance, with promising earnings growth projections and a strong market position.
Wall Street Analysts Predict 35.64% Growth Potential for Inogen (INGN): Is Such a Surge Possible?
Stock Performance and Price Targets: Inogen (INGN) shares have risen 25.2% recently, with Wall Street analysts suggesting a mean price target of $11, indicating a potential upside of 35.6%, despite some estimates predicting declines.
Analyst Insights and Earnings Revisions: Analysts show growing optimism for INGN's earnings, with a Zacks Rank #2 (Buy) reflecting strong agreement on positive earnings revisions, which historically correlate with stock price movements.
Inogen Second Quarter 2025 Earnings: Beats Expectations
Inogen's Financial Performance: Inogen reported a revenue of US$92.3 million for 2Q 2024, a 4% increase from the previous quarter, with a net loss of US$4.15 million, which is a 26% improvement from the prior period. The company's earnings per share also improved significantly, surpassing analyst expectations.
Industry Outlook and Stock Movement: Revenue growth is projected at 6.2% annually over the next three years, while the Medical Equipment industry in the US is expected to grow by 8.2%. Additionally, Inogen's shares have increased by 4.3% over the past week, despite one identified warning sign regarding the company.
Inogen Stock Gains Following Q2 Earnings Beat, Revenues Up Y/Y
Financial Performance: Inogen, Inc. reported an adjusted loss per share of 2 cents for Q2 2025, an improvement from a 7-cent loss in the previous year, with revenues of $92.3 million, up 4% year-over-year, surpassing estimates.
Market Outlook and Developments: The company introduced new products aimed at enhancing patient care while facing challenges such as declining direct-to-consumer sales and rental revenues; it expects revenue growth of approximately 6% for 2025.
Inogen Launches Aurora CPAP Masks, Expanding into Sleep Therapy Market
- Product Innovation: Inogen's launch of the Aurora CPAP masks marks a significant milestone in its respiratory care portfolio, aimed at providing high-quality masks for patients with obstructive sleep apnea, thereby expanding market opportunities.
- Market Positioning: Designed for superior comfort and reliability, the Aurora masks enhance Inogen's competitiveness in the rapidly growing sleep therapy market, with plans to leverage existing distribution channels to strengthen relationships with healthcare providers.
- User Feedback: A patient-use study involving 140 participants revealed that the majority reported high satisfaction with the Aurora masks, indicating strong market acceptance and potential for sales growth.
- Technical Advantages: Featuring high-quality headgear and medical-grade silicone cushions, the Aurora masks provide a comfortable fit and are universally compatible with most CPAP devices, meeting FDA 510(k) standards for safety and performance.
Inogen Launches Aurora CPAP Masks, Expanding into Sleep Apnea Market
- Product Innovation: Inogen's launch of the Aurora CPAP masks marks a significant advancement in its home respiratory solutions, aimed at addressing the needs of patients with obstructive sleep apnea, thereby broadening its market coverage.
- Market Opportunity: Designed for superior comfort and reliability, the Aurora masks are expected to enhance Inogen's competitiveness in the rapidly growing sleep therapy market, further increasing its market share.
- Customer Satisfaction: A patient-use study involving 140 participants revealed that the majority reported high satisfaction with the Aurora masks, establishing a solid foundation for Inogen's market entry.
- Strategic Partnerships: Inogen plans to leverage its existing distribution channels and partnerships to bring the Aurora masks to market, strengthening relationships with healthcare providers and reinforcing its leadership position in home respiratory care.
Three MedTech Pioneers Transforming Healthcare by 2026: AVAH, INGN, and CCLD
Healthcare Innovation Focus: Investors are increasingly interested in companies that innovate healthcare delivery to reduce costs and improve quality, particularly in ambulatory and home care settings, amid rising healthcare expenses and workforce shortages.
Aveanna Healthcare Overview: Aveanna Healthcare is positioned for growth with a diverse service mix in home care, expecting significant revenue increases and operational momentum, despite potential risks from labor costs and reimbursement policies.
Inogen's Market Position: Inogen specializes in portable oxygen concentrators, showing signs of recovery and growth through innovation and cost discipline, making it a notable player in the respiratory care market for 2026.
CareCloud's Technological Advancements: CareCloud offers a comprehensive suite of healthcare IT solutions, focusing on AI-driven efficiencies to improve operational performance, with promising earnings growth projections and a strong market position.
Wall Street Analysts Predict 35.64% Growth Potential for Inogen (INGN): Is Such a Surge Possible?
Stock Performance and Price Targets: Inogen (INGN) shares have risen 25.2% recently, with Wall Street analysts suggesting a mean price target of $11, indicating a potential upside of 35.6%, despite some estimates predicting declines.
Analyst Insights and Earnings Revisions: Analysts show growing optimism for INGN's earnings, with a Zacks Rank #2 (Buy) reflecting strong agreement on positive earnings revisions, which historically correlate with stock price movements.
Inogen Second Quarter 2025 Earnings: Beats Expectations
Inogen's Financial Performance: Inogen reported a revenue of US$92.3 million for 2Q 2024, a 4% increase from the previous quarter, with a net loss of US$4.15 million, which is a 26% improvement from the prior period. The company's earnings per share also improved significantly, surpassing analyst expectations.
Industry Outlook and Stock Movement: Revenue growth is projected at 6.2% annually over the next three years, while the Medical Equipment industry in the US is expected to grow by 8.2%. Additionally, Inogen's shares have increased by 4.3% over the past week, despite one identified warning sign regarding the company.
Inogen Stock Gains Following Q2 Earnings Beat, Revenues Up Y/Y
Financial Performance: Inogen, Inc. reported an adjusted loss per share of 2 cents for Q2 2025, an improvement from a 7-cent loss in the previous year, with revenues of $92.3 million, up 4% year-over-year, surpassing estimates.
Market Outlook and Developments: The company introduced new products aimed at enhancing patient care while facing challenges such as declining direct-to-consumer sales and rental revenues; it expects revenue growth of approximately 6% for 2025.
